27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Moderna Inc (NASDAQ:MRNA) has exercised its option to license Autolus Therapeutics plc's (NASDAQ:AUTL) proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics.
- This follows an original agreement with Moderna announced in August 2021, granting Moderna an exclusive option to license Autolus' proprietary binders for up to four immuno-oncology targets for incorporation in certain mRNA therapeutics.
- Related: Moderna Shares Are Surging After Merck Exercised Personalized Cancer Vaccine Pact.
- On exercise of the option, Autolus has received an option exercise payment and is eligible to receive development and commercial milestone payments for each product successfully commercialized.
- In addition, Autolus would receive royalties on net sales of all products commercialized under the agreement.
- Price Action: AUTL shares are up 8.89% at $3.24 on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!